CLINICAL TRIALS, STUDIES, REGISTRIES, DATA
Less than 1 min.Read

First Patient Treated in U.S. Pilot Trial Evaluating the eShunt System in Patients with Normal Pressure Hydrocephalus

CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, announced completion of the first eShunt® procedure in the United States.

The study, ‘US Pilot Study of the CereVasc eShunt System in Normal Pressure Hydrocephalus (NPH)’, is being conducted under an investigational device exemption (IDE) approved by the US Food and Drug Administration (FDA) earlier this year.

The patient was treated at Yale Medicine by Dr. Charles Matouk, Associate Professor of Neurosurgery; Vice Chair of Clinical Affairs, Neurosurgery; Chief, Neurovascular Surgery; Director, Neurovascular/Endovascular Fellowship. “We are pleased to participate in this study of the eShunt System, a promising device with the potential to transform the care of patients with NPH using a minimally invasive approach as opposed to open surgery,” said Dr. Matouk.

“This study, which will evaluate the safety and efficacy of the eShunt System, represents a significant milestone for the company and the neurovascular field, as we advance our solution for the millions of people across the world that suffer from NPH through the clinical pathway,” said Dan Levangie, Chairman and CEO of CereVasc. Details of the trial can be found here.

SourceCereVasc, Inc.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

0
Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

0
Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

0
EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

0
The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

0
Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York, No. Carolina
United States
Phone Number: 1.561.316.3330